Drugs / CN202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05028478 | Oct 2021 → Feb 2023 | hematopoietic and lymphoid cell neoplasm, metastatic neoplasm | Curon Biopharmaceutical (Australia) Co Pty Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CN202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05028478 ↗ |
| Route | Intravenous | “CN202 by IV infusion” NCT05028478 ↗ |